Purpose: Homeostasis Model Assessment of β-cell function and Insulin Resistance
Introduction
Type 2 diabetes (T2D) represents the fastest growing non-communicable disease epidemic world-wide 1 . Fasting hyperglycaemia is one of the criteria used for type 2 diabetes (T2D) diagnosis, and fasting insulin (FI) levels are indicative of insulin sensitivity in peripheral tissues, but neither measure provides mechanistic insights into insulin secretion and action 2 . Homeostasis Model Assessment of β-cell function (HOMA-B) and Insulin Resistance (HOMA-IR) can be derived from FG and FI concentrations and are two commonly used fasting state glycaemic indices elucidating pathophysiological processes in T2D [3] [4] [5] [6] [7] [8] [9] [10] [11] . HOMA-B reflects the function of β-cells in terms of their ability to secrete insulin, whereas HOMA-IR is a surrogate measure of insulin sensitivity.
Pathophysiology of T2D and metabolic syndrome, as well as epidemiological and genetic studies suggest that there is a shared aetiology between cardiometabolic phenotypes, variability of glycaemic traits in individuals without diabetes, and T2D 9, [12] [13] [14] .
Sedentary lifestyle and major risk factors of T2D induce low-grade inflammation, which consequently leads to overt diabetes in individuals with more pronounced and prolonged inflammatory response 15 and insulin resistance. However, genetic relationships between these traits are not established. Moreover, metabolic syndrome is a pro-thrombotic state due to the inhibition of the fibrinolytic pathway, another proposed risk factor of T2D related to insulin resistance and inflammation 16, 17 , but little is known about their shared genetic risk factors. The shared genetic aetiology within cluster of cardiometabolic traits was only recently reported through estimation of genetic correlations 18, 19 .
Our understanding of biological processes shared between β-cell function and insulin resistance, reflected by HOMA-B/-IR, and a range of epidemiologically related traits and diseases, such as T2D, could be informed by dissecting the patterns of their genetic relationships. Genome-wide association studies (GWAS) have identified over 70 loci associated with fasting glucose (FG) and/or FI levels in non-diabetic European descent individuals 20 . However, to date, only ten HOMA-B loci, including ADCY5, ARAP1(STARD10), DGKB, FADS1, GLIS3, GCK, G6PC2, MTNR1B, TCF7L2, and SLC30A8, and three HOMA-IR loci (GCKR, IGF1/SC4MOL, TCERG1L) have been described in GWA studies in European/African American descent populations [21] [22] [23] [24] [25] . This is mostly attributable to underpowered studies, since HOMA-B and HOMA-IR calculations require assessment of both FG and FI in the same individual. If either of these two primary fasting measures is missing for an individual, their HOMA indices cannot be derived and such individuals do not contribute to GWAS of HOMA indices. Similarly, missing FG or FI measurement in an entire cohort precludes involvement of such study in GWAS meta-analyses of HOMA indices (Figure 1) . As a consequence, HOMA-B/-IR GWAS meta-analyses usually feature dramatically smaller sample sizes compared to FG/FI GWAS. Previously published HOMA-B/-IR discovery analyses by the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) suffered from about 20% sample size and power losses for analytically inferred indices 21 , which has held up the progress of understanding the molecular mechanisms behind insulin secretion and sensitivity composite measures through locus discovery in recent years 26,27;28,29 . The Genome Wide Inferred Statistics (GWIS) method provides an approximation of the GWA summary statistics for any derived variable that is a function of primary phenotypes, when such statistics, means and covariances of the constituent primary phenotypes are available or can be approximated with reasonable precision 30 . Unlike GWAS, the GWIS can accommodate information from individuals or cohorts, where any of the primary phenotypes is assessed. Moreover, the GWIS accommodates any degree of overlap between individuals from studies contributing data for primary traits. In this study, we applied GWIS methodology 30 and derived the summary statistics for HOMA indices based on recent FG and FI GWAS meta-analysis summary statistics from the MAGIC (Lagou et al., manuscript in preparation).
The aims of this study were three-fold: (i) to infer analytically HOMA-B/-IR GWIS based on the FG/FI GWAS meta-analysis summary statistics from the MAGIC consortium and evaluate the sensitivity of GWIS methodology; (ii) to use the obtained summary statistics to define the effects of T2D, FG/FI and HbA1C loci on insulin secretion and action through their effects on HOMA-B/-IR; and (iii) to explore the genetic relationships between HOMA-B/-IR, cardiometabolic, and inflammatory traits. where FG is measured in mmol/l and FI is in mU/l units 31 . where division by 6.945 was introduced to convert FI from pmol/l to mU/l units. The GWIS method requires, in addition to genome wide summary statistics for FG and FI, the population mean of FG and FI, the phenotypic correlation between FG and FI and sample overlap across the studies, included in both meta-analyses studies, to correct for dependence between the FG and FI GWAS (details in Supplemental Materials and Methods and example scripts in Data Access). Overall, we calculated the effect estimates We run the LDSC 33 between the GWIS-inferred and published summary statistics for HOMA-B and HOMA-IR, to obtain the LDSC intercept for the GWIS-inferred HOMA-B/-IR and to estimate the genetic correlation between inferred and published data. We used LDSC intercept to correct the inferred summary statistics for any inflation (Supplementary Materials and Methods).
Methods

Phenotypes
GWIS for HOMA-B/-IR
Genome-wide imputation using summary statistics
We implemented a novel methodology developed within SS-imp software tool that enables genome-wide imputation from denser reference panels 34 and imputed the analytically inferred HOMA-B/-IR GWIS to 1000 Genomes project variant density and compared the findings with the lower variant density directly inferred GWIS.
Functional and regulatory elements enrichment analysis
We applied the GARFIELD 35 tool v2 on the meta-analysis results to assess enrichment of the HOMA-B/HOMA-IR associated variants within functional and regulatory features.
GARFIELD enables checking for genic annotations, chromatin states, DNaseI hypersensitive sites, transcription factor (TF) binding sites, FAIRE-seq elements and histone modifications, among others, in a number of publicly available cell lines. We considered significant enrichment to be present if the GWIS signal and the functional annotation signal significantly co-localized, i.e. PGWIS<5x10 -8 and Penrichment<1.2x10 -5 after correction for 2,040 annotations.
Genetic correlation between HOMA indices and other phenotypes
To evaluate the shared genetic aetiology, we applied the LDSC approach 33 to HOMA-B/-IR and publicly available meta-analysis summary statistics for T2D, 13 glycaemic and 17 cardiometabolic phenotypes (sample size, ethnicity, reference and source of the data presented in Table S3 ). We defined an extended group of cardiometabolic phenotypes and related traits by including chronic kidney disease (CKD) and its markers (Estimated glomerular filtration rate (eGFR) based on creatinine and cystatin C) 36 ; systolic and diastolic blood pressure (SBP/DBP) and hypertension (HTN) 37 to explore the genetic relationships between cardiometabolic traits and HOMA-B/-IR. We expanded our analysis to five inflammatory markers, including adiponectin 38 , plasminogen activator inhibitor 1 (PAI-1) 39 , C-reactive protein (CRP) 40 , intercellular adhesion molecule 1 (ICAM-1) 41 , white blood cell counts (WBC) 42 ). The five inflammation phenotypes were obtained with permission of Cross Consortia Pleiotropy (XC-Pleiotropy) Group (Table   S3 ).
Results
GWAS for HOMA-B/-IR
We inferred analytically the HOMA-B/-IR GWAS summary statistics using the summary 13 . We also confirmed associations at 10 established HOMA-B/FG loci ( Figure S5a , Table 1 ) 13, 21, 43 . The HOMA-IR GWIS provided three novel loci at LYPLAL1/SLC30A10, PER4, PPP1R3B and confirmed established loci at GCKR and IGF1 21 (Figure S5b , Table 1 ).
Imputation using new tool SS-imp 34 for summary statistics to 1000G density highlighted small difference from the lead variants at HOMA loci imputed to HapMap2 reference panel ( Table S4 ). New lead 1000G-imputed variants at TCF7L2, ARAP1[STARD10] for HOMA-B, and at GCKR (rs11336847) for HOMA-IR, were in strong (r 2 >0.8) LD, and at G6PC2 (rs580670 for HOMA-B in moderate (r 2 >0.6) LD with HapMap2 lead variants (Table1).
GWIS requires FG/FI population mean estimates to infer summary statistics for
HOMA-B/-IR, which vary across studies. We performed a set of sensitivity analyses,
where we allowed mean estimates to fluctuate between reasonable values. These (Figure 2b) 50, 51 .
Nine of eleven genome-wide significant HOMA-B loci and four loci of suggestive significance (GCK, PDX1, CDKAL1, FTO) have established effects on HbA1C levels 44 (Figure   2e ). The HbA1C loci have been classified into erythrocytic or glycaemic, but a number of them remain unclassified. We suggest that five unclassified HbA1c loci (PHB2, FNDC3B, GAS6, SYF2, CERS2) are glycaemic as they exert nominal effects on HOMA-B. Similarly, the abovementioned PHB2, FNDC3B, GAS6 as well as ATA2B and FOXN2 are nominally associated with HOMA-IR and therefore are likely glycaemic.
Enrichment in functional elements for HOMA-B/-IR associations
The enrichment analysis using the GARFIELD software did not yield statistically significant co-localization signals neither for HOMA-B nor HOMA-IR. We observed suggestive evidence (P<0.05) for an enrichment of the HOMA-B associated variants within several pathophysiologically relevant tissues, including blood, liver and brain.
Both HOMA-B and HOMA-IR associated variants showed also suggestive evidence for enrichment in a number of annotations within K562 (human immortalised myelogenous leukemia cell line) and HepG2 (human immortalised liver carcinoma cell line) cells, including transcription start cites, weak enhancers among chromatin states, histone modifications, transcription factor binding cites and FAIRE-seq elements (Figure S7) .
Genetic relationships between HOMA indices and other phenotypes.
LDSC 33 was applied to estimate the genome-wide genetic correlation between HOMA-B/-IR and 36 other phenotypes falling into five broad domains (Table S8) For HOMA-IR, we saw significant correlations with FI (rg=0.98, P=<0.001), FG (rg=0.49, P=1.37×10 -9 ), HbA1C (rg=0.28, P=0.02) and T2D (rg=0.56, P=2.31×10 -9 ), in accordance with epidemiological observations. The genetic correlation between HOMA-B from our largest to date GWAS confirmed initial observations 18 on the strong genetic correlation with FI (rg=0.80, P=8.77×10 -72 ). In accordance with previous reports, the correlation with FG (rg=-0.32, P=0.05) and relationship with T2D (rg=0.05, P=0.71) were not significant after multiple testing corrections 18, 52 . Other indices of glucose homeostasis, including the insulin sensitivity index, ISI, without adjustment for BMI, were inversely correlated with both HOMA indices (rgHOMA-B/-IR=-0.90/-1.04, PHOMA-B/-IR=1.20×10 -5 /2.71×10 -8 ). We did not find significant genetic correlations between HOMA-B/-IR and other glycaemic traits, which is likely due to small GWAS sample sizes for those phenotypes ( Table S8 ). Triglycerides (TG) and all obesity traits were directly correlated with both HOMA-B/-IR, similarly to a previous report that used enrichment analysis approaches 13 . We found no significant genetic correlations between HOMA-B/-IR and traits in the domain of T2D complications with the exception of Estimated Glomerular 
Effects of fasting glycaemic trait loci on PAI-1 variability
We followed up the observation from genome-wide genetic correlation estimates by evaluation of the effects of FG/FI loci on PAI-1 and HOMA-B and HOMA-IR, respectively (Figure 4) . While only four FG loci (PPP1R2B, MTNR1B, CRY2 and GCKR) showed at least nominally significant effects on PAI-1 ref39 , the direction of their effects was variable.
Interestingly, among FI loci, at least half of the loci had nominal association with PAI-1.
At only two loci (PELO and GCKR), FI increasing allele was associated with lower PAI-1 levels, GCKR variant effect being in line with its established mutational mechanism leading at the same time to higher FG and lower triglycerides levels 51 . At the same time, among four established PAI-1 loci, rs1801282-A (coding SNP, Pro12Ala) at PPARG is an established T2D risk 53 and insulin resistance 29 variant leading to higher PAI-1 levels.
Discussion
We report the largest GWAS to date of HOMA-B and HOMA-IR indices in nondiabetic individuals of European origin, inferred analytically from FG and FI GWAS metaanalysis summary statistics and imputed using novel methodology 34 to 1000 Genomes Project variant density. The application of GWIS methodology brought the total count of HOMA-B/-IR loci to 11/5, respectively, and brought the analytical sample size up to ~75,240 individuals. This GWIS-based analysis revealed one novel HOMA-B and three novel HOMA-IR loci. We highlighted the strongest novel positive genetic correlations between non-glycaemic trait PAI-1 and HOMA-B/-IR. We also reported novel positive genetic relationships between CRP and HOMA-B/-IR, as well as inverse relationships between adiponectin and HOMA-IR. We demonstrated that GWIS of both HOMAs produced more precise SNP effect parameter estimates, and thus gained power, compared to the previous GWAS 21 . The results of LDSC 33 analysis confirmed that the gain in power in GWIS did not arise from the introduction of spurious inflation due to population stratification or other biases. High insulin and glucose levels, insulin resistance and β-cell dysfunction characterize the pathophysiology of T2D. However, the exact mechanism of genetic interrelationships between the metabolic processes and disease is still unclear. Amongst the established T2D loci 45, 46, 48 we investigated in relation to HOMA indices GWIS results (Tables S5-S7), only 41/30 have at least nominal effect on HOMA-B/-IR variability, respectively, highlighting an incomplete overlap between genetic variants affecting normal glucose homeostasis and processes involved in T2D pathogenesis. Insulin resistance and β-cell function may have distinct impact on susceptibility to T2D 28 , and mechanistically T2D loci can be related to a specific biological process affecting insulin secretion, resistance or processing 59 . Effects of T2D loci follow the main subdivisions into β-cell, hyperglycaemia, proinsulin and insulin resistance groups 29 . The group of established T2D loci that influence insulin resistance or fasting insulin has been undercharacterised, most probably, due to low power of respective endophenotype GWAS meta-analyses 21, 60 . Empowered by analytically inferred HOMA-IR GWAS, we demonstrated that the group on insulin resistance loci is larger than described before and comparable to that of β-cell loci. As expected from epidemiological studies, FG loci also affect HOMA-B values (Figure S5) , whereas FI variants have most prominent effect on HOMA-IR.
We confirmed the evidence of shared genetic effects between HOMA-B and T2D risk at several loci, manifested by inverse relationships 28,29 . However, the effect of left truncation for FG levels to define non-diabetic individuals in general population leads to seemingly improved β-cell function through positive HOMA-B values for the insulin resistance loci. In fact, we did not observe any genetic correlation between HOMA-B and T2D using summary statistics from the latest GWAS meta-analyses. In parallel, we however demonstrated that HOMA-B loci, associated with a decrease in β-cell function, exert their effects by both increasing and decreasing insulin resistance (Figure 2a-b) .
Inflammation markers PAI-1 and CRP showed strong positive genetic correlation with both HOMA-B/-IR measures. The correlation of these markers was stronger with fasting insulin resistance. CRP is a marker of increased cardiovascular risk 61, 62 and PAI-1 is associated with CAD 63 and myocardial infarction 64 , both high risk factors in T2D.
Importantly, PAI-1 is a fibrinolytic and inflammatory marker, which was proposed and confirmed in epidemiological studies as an independent risk factor for T2D 65, 66 . In our study among non-glycaemic traits, PAI-1 showed the strongest genetic correlation with fasting insulin resistance, a pathophysiological process leading to T2D. Moreover, when we looked at the individual effects of FG/FI variants on PAI-1 variability, variant alleles associated with higher FI grouped around increased levels of PAI-1, while there was no clear pattern of such an effect for FG variants. From pathophysiological point of view, the clustering of hyperinsulinaemia, dysglycemia, dyslipidemia, and hypertension as cardiovascular risk endophenotypes in T2D occurs around insulin resistance, and in the presence of elevated PAI-1 levels, leads to fibrinolytic dysfunction, increased thrombotic risk 17, 67 , and induces local or systemic low-grade inflammation. Taken together, evidence from our study provides novel genetic support for the need to dissect in better detail these deficient mechanisms in the early pathogenesis of T2D.
Noteworthy, we observed no significant genetic correlation between HOMA-B/-IR and CAD, hypertension, SBP and DBP, which could indicate that the associations between HOMA-B/-IR and PAI-1 and CRP are strictly due to inflammatory pathways involved in T2D risk. Contrary to expectations from epidemiological studies, we neither observed correlation between adiponectin and HOMA-B for genetic effects using the GWAS summary statistics, whilst the respective genetic correlation with HOMA-IR may be through its association with obesity, since adiponectin is secreted in adipose tissue.
Alternatively, it can be due to its involvement in inflammatory processes in T2D pathogenesis 68 . Analysis of CKD and its marker eGFR based on creatinine did not yield statistically significant genetic correlations; only eGFR based on cystatine C for HOMA-B did so. The latter could reflect the association between cystatine and metabolic syndrome 69 , whose definition includes T2D risk factors such as insulin resistance and abnormal fat distribution 70 .
Finally, we reported novel significant positive genetic correlation between HOMA- Our study provides additional evidence for the GWIS method as a powerful tool for future GWAS studies of analytically derived phenotypes. Our work also suggests that GWAS meta-analysis of summary statistics is a useful source of information for follow-up analyses, including inferences about genetic correlations and mechanistic characterisation of the specific trait pathophysiology through their effects on other related phenotypes. 
